The present invention provides a novel compound having a superior activity as an ERR-α modulator and useful as an agent for the prophylaxis or treatment of ERR-α associated diseases.
The present invention relates to a compound represented by the formula
wherein each symbol is as defined in the specification, or a salt thereof.
The present invention provides a novel compound having a superior activity as an ERR-α modulator and useful as an agent for the prophylaxis or treatment of ERR-α associated diseases.
The present invention relates to a compound represented by the formula
wherein each symbol is as defined in the specification, or a salt thereof.
[EN] NITROGEN-CONTAINING HETEROCYCLIC COMPOUND<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE CONTENANT DE L'AZOTE
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2013018929A1
公开(公告)日:2013-02-07
The present invention provides a novel compound having a superior activity as an ERR-α modulator and useful as an agent for the prophylaxis or treatment of ERR-α associated diseases. The present invention relates to a compound represented by the formula (1) wherein each symbol is as defined in the specification, or a salt thereof.